Kornimate/medical-research-clean huggingface dataset:
postoperative pain and venipuncture pain

Conditions: Pain

Summary: association between venipuncture pain and postoperative pain

association will be find between venipuncture pain and postoperative pain in sleeve gastrectomy patients. also we can study with pain catastrophising scale.

Eligibility criteria:
inclusion criteria: * sleeve gastrectomy exclusion criteria: * psychotic illness
exposure therapy for auditory sensitivity in autism

Conditions: Sensory Disorders; Autism; Autism Spectrum Disorder; Autism With High Cognitive Abilities; Autistic Behavior; Hyperacusis

Summary: auditory hyper-reactivity affects up to 66% of children with autism spectrum disorder (asd) and has been linked to greater stress and anxiety for children and their families. exposure and response prevention (e/rp) is highly effective for reducing obsessive/compulsive behaviors in children with both ocd and asd. this study is the first to assess the feasibility and efficacy of e/rp for auditory sensory hyper-reactivity in asd.

sensory processing difficulties have been well documented in children with autism spectrum disorder (asd). in fact, "hyper- or hypo-reactivity to sensory input" has recently been added to the diagnostic criteria of this disorder. hyper-reactivity features are particularly disruptive to children's abilities to engage in everyday activities and pose a significant problem for patients and their families. in children with high functioning pervasive developmental disorder, hyper-sensitivity is associated with symptoms of anxiety and depression. for sensory processing difficulties, children with asd are primarily referred to occupational therapy (ot) services for treatment. these patients are also often seen by mental health professionals to address related disorders such as anxiety, adhd and behavior problems. currently, there are no evidence based approaches for specifically addressing auditory hyper-reactivity in asd. exposure and response prevention (e/rp), derived from systematic desensitization, is highly effective at reducing avoidance behaviors associated with phobias and obsessive and compulsive disorder (ocd). in mental healthcare settings, er/p has been shown to be effective for reducing compulsive behaviors in children with ocd and concurrent asd. e/rp has also been piloted for treating restricted, repetitive behaviors in asd and demonstrates good feasibility. e/rp may also be useful for reducing aversive responses to auditory stimuli in children with asd. occupational therapists (ot) are the primary service for providing treatment for sensory processing and arousal level modulation difficulties in children with asd. thus, ots are potentially well suited to provide an e/rp aimed at reducing sensory hyper-reactivity in asd. this study will investigate the feasibility and efficacy of utilizing an e/rp approach for treating auditory hyper-reactivity in asd.

Eligibility criteria:
inclusion criteria of children: * autism spectrum disorders (asd) diagnosis with symptoms of auditory hyper-sensitivity/reactivity. * verbal communication skills for utilizing the subjective units of distress (sud) scale (no cut-off for iq). exclusion criteria of children * behavioral diagnosis of oppositional defiant disorder or conduct disorder * history of child abuse that is related to sound sensitivity

Keywords: autism sensory over-responsiveness auditory hyper-sensitivity auditory processing exposure therapy exposure and response prevention cognitive behavior therapy occupational therapy
exercise training effects on metabolic syndrome: interactions with medication

Conditions: Exercise Therapy; Metabolic Syndrome X; Cardiorespiratory Fitness

Summary: to analyze the effects of different exercise training modalities (continuous, intervallic, and resistance training) on cardiorespiratory and metabolic fitness of metabolic syndrome patients when this training interacts with their habitual medication.

objective: the purpose is to study in a group of adults with metabolic syndrome and obesity, the effects of different modalities of exercise training on cardiorespiratory and metabolic fitness. the main objective is to weight the effects of exercise training separately and in conjunction with the subject's habitual pharmacological treatment to identify the best combination of drug and exercise. methods and design: randomized, pretest-posttest control group experimental design. project developed in a single center with the collaboration of the regional public health system. subjects: will be referred by their primary care physicians to our study unit. up to 40 subjects all of them with metabolic syndrome will be recruited (at least 20% women). measurements: 1. specifically, the investigators, will study cardiovascular adaptations that increase, i) maximal aerobic capacity measured by vo2max, ii) anaerobic and respiratory compensation point ventilatory thresholds, iii) arterial stiffness, measured by pulse wave velocity (sphygmocor system), v) central and peripheral blood pressure, and iv) biological markers of endothelial dysfunction using reactive hyperemia with a laser doppler fluxmeter in central and peripheral blood vessels. 2. the metabolic adaptations under study will include, i) insulin sensitivity by homa-ir, ii) fat oxidation by indirect calorimetry

Eligibility criteria:
inclusion criteria: * metabolic syndrome patients diagnosed according to the international diabetes federation consensus of 2009 (alberti, et al., circulation). * 18-65 years old exclusion criteria: cardiovascular disease or musculo-skeletal that prevents them from being able to perform intense exercise. * respiratory failure * patient ends * pregnancy
opioid prescription after cesarean trial

Conditions: Pregnancy Related; Opioid Use; Pain

Summary: non-inferiority randomized trial of 5,500 women with a cesarean delivery randomized prior to discharge to either an individualized opioid prescription protocol (iopp) that includes shared decision making or to a fixed opioid prescription of 20 tablets of oxycodone 5mg.

this was a non-inferiority multi-center unblinded randomized trial of 5,500 women undergoing a cesarean delivery who were randomized before discharge to either an individualized opioid prescription protocol (iopp) that includes shared decision making or to a fixed opioid prescription of 20 tablets of oxycodone 5mg. the primary endpoint was the presence/absence of moderate to severe pain at 1 week after discharge. moderate to severe pain was defined as a value of 4 or higher on the brief pain inventory worst pain scale (0 to 10) in the last 24 hours. consenting women were assigned in a 1:1 ratio to one of the two arms using a secure internet based randomization system maintained centrally by the data coordinating center (dcc). randomization was stratified by site. women were followed through 90 days postpartum.

Eligibility criteria:
inclusion criteria: * post cesarean delivery (combined vaginal/cesarean deliveries are not eligible) * singleton, twin or triplet gestation exclusion criteria: * an opioid prescription filled during the current pregnancy * known history of opioid use disorder, by medical record review * contraindication to opioids (oxycodone) * contraindications to both acetaminophen and ibuprofen * significant surgical procedures (e.g., hysterectomy) prior to randomization as pain trajectory will be completely different * fetal or neonatal death prior to randomization * inability to randomize within 1 day before planned discharge from the hospital * inability to participate in shared decision making as assessed by research staff * language barrier (non-english or spanish speaking) * participation in this trial in a previous pregnancy * participation in another intervention study that influences the primary outcome in this trial
vitamin d treatment in ulcerative colitis

Conditions: Ulcerative Colitis; Inflammatory Bowel Disease

Summary: the purpose of this study is to test blood and tissue samples of people with ulcerative colitis (uc) to see what effects vitamin d3 may have on the immune system. this research is being done because it could lead to the development of new treatment for people with inflammatory bowel disease (ibd).

the primary endpoint of the trial is the change in colonic permeability as a global assessment of vitamin d3 effects throughout the colon in patients with ulcerative colitis. secondary endpoints will be changes in colonic tight junction protein expression, and their relationship to serum vitamin d level, vdr expression, inflammatory cytokines, and histologic inflammation

Eligibility criteria:
inclusion criteria: * patients must be over 18 years of age * have a diagnosis of uc as confirmed by histology. * uc patients must have active but mild disease as confirmed by a mayo clinic endoscopy score from 2-4, * not requiring medication adjustment during the trial. * patients must be capable of understanding the purpose, risks and expectations of study participation and willing to provide written informed consent. exclusion criteria: * individuals on vitamin d or laxative therapy (except for purposes of endoscopy preparation), * uc patients with fulminant colitis or active c difficile or other colonic infections, * age\<18 year old, * individuals with bleeding disorders will be excluded from the study.

Keywords: ulcerative colitis inflammatory bowel disease ibd vitamin d
erlotinib for treatment of psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to determine whether erlotinib is effective in the treatment of psoriasis.

psoriasis vulgaris is a disease that affects 25 million people in north america and europe. it often presents in late adolescence and usually persists for life. current therapies target specific immune molecules that are implicated in the cause of this disease. for example, biologic agents that are used in severe psoriasis are aimed at inflammatory mediators. these therapies have been proven to be effective but also have their limitations.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of moderate to severe psoriasis * must have documented moderate to severe psoriasis by the physician's global assessment (pga) and the psoriasis area severity index (pasi) * must be able to swallow tablets * must be able to provide written informed consent * subjects with reproductive potential (menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures throughout the study and thirty days after discontinuation of study drug. women of childbearing potential must provide negative pregnancy test (serum or urine) within 14 days prior to randomization. exclusion criteria: * use of concurrent agents/therapies for psoriasis * bilirubin \> 3 x ≥ uln or moderate to severe hepatic impairment * pregnant or breast-feeding females * subjects currently receiving other anticancer treatments * subjects currently receiving other biologic treatments * subjects currently receiving blood thinners (warfarin or heparin) * subjects who currently smoke * subjects with other skin disease which in the opinion of the investigator, would inhibit the ability to use the pga and pasi evaluation methods

Keywords: psoriasis double-blind randomized placebo-controlled erlotinib efficacy
vasopressin versus tranexamic acid for control of blood loss related to abdominal hysterectomy

Conditions: Uterine Surgery

Summary: to find the best option to reduce blood loss related to abdominal hysterectomy (ah), the present randomized double-blinded study sought to compare the effects of locally administered vasopressin (vp) and tranexamic acid (txa) on blood loss in women submitted to ah for benign lesions.

to find the best option to reduce blood loss related to abdominal hysterectomy (ah), the present randomized double-blinded study sought to compare the effects of locally administered vasopressin (vp) and tranexamic acid (txa) on blood loss in women submitted to ah for benign lesions. interventions study interventions patients in all groups will receive identically looking pharmaceutical preparations which differ according to the study group 1. vasopressin group just before beginning of ah, patients in this group will be injected with a 10-ml syringe containing 10 units of vp (5 ml bilaterally), 1 cm medial to the uterine vessels in the most distal area of the lower uterine segment not to compromise the bladder. if this site is not accessible, patients will be alternatively injected in the midline at the fundus (okin et al., 2001). in addition, and just before closure of peritoneum, 100 ml of normal saline (ns) will be applied topically over the raw surface. 2. tranexamic acid group just before ah, patients in this group will be injected with a 10-ml syringe containing 10 ml of ns (5 ml bilaterally) as described above. just before closure of peritoneum, 1.5 g of txa mixed in 100 ml of ns will be applied topically over the raw surface (mitra et al., 2022). 3. control group just before ah, patients in this group will be injected with a 10-ml syringe containing 10 ml of ns (5 ml bilaterally) as described above. in addition, and just before closure of peritoneum, 100 ml of normal saline (ns) will be applied topically over the raw surface.

Eligibility criteria:
inclusion criteria: - patients will be included in the present study if they are indicated for abdominal hysterectomy for benign lesions. exclusion criteria: * history of coagulation or bleeding disorders or * if they were under antithrombotic treatment. * associated malignancy, renal impairment or allergy to ta.
gefitinib and berberine in the first-line treatment of lung adenocarcinoma with egfr mutation

Conditions: Lung Adenocarcinoma; EGFR Mutation

Summary: rationale: advanced non-small-cell lung cancer (nsclc) patients harboring epidermal growth factor receptor (egfr) mutations (del19 or l858r) show an impressive progression-free survival between 9 and 11 months when treated with gefitinib. combination of gefitinib and berberine could improve efficacy in lung cancer with egfr mutation in vivo and vitro. the investigators hypothesize that progression-free survival could be improved by combination of gefitinib and berberine.

strong lipogenic activity and high expression of sterol regulatory element-binding protein 1 (srebp-1) were found in gefitinib-resistance nsclc cells. berberine, an effective suppressor of srebp1 and lipogenesis regulated through ros/ampk pathway, selectively inhibited the growth of gefitinib-resistance nsclc cells but not that of normal cells. it effectively caused mitochondrial dysfunction, activated reactive oxygen species (ros)/ampk pathway and finally suppressed cellular lipogenesis and cell proliferation. addition of ros blocker, ampk inhibitor and palmitic acid significantly reduced the effect of berberine. in in vivo study, treatment of berberine led to significant inhibition of mouse tumor xenograft growth.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * ecog performance status 0-2 * adequate haematological function, coagulation, liver function and renal function * pathological diagnosis of predominantly non-squamous, non-small-cell lung cancer (nsclc) * tnm version 7 stage iv disease including m1a (malignant effusion) or m1b (distant metastasis), or locally advanced disease not amenable to curative treatment (including patients progressing after radiochemotherapy for stage iii disease) * measurable or evaluable disease (according to recist 1.1 criteria). * centrally confirmed egfr exon 19 deletion (del19) or exon 21 mutation (l858r) exclusion criteria: * patients who have had in the past 5 years any previous or concomitant malignancy except adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ breast carcinoma. patients with any known significant ophthalmologic anomaly of the ocular surface * patients who received prior chemotherapy for metastatic disease * patients who received previous treatment for lung cancer with drugs targeting egfr or vegf * pregnancy

Keywords: lung adenocarcinoma egfr mutation gefitinib berberine
identification of psychosocial factors associated with diagnostic delay in advanced basal cell carcinoma

Conditions: Carcinoma, Basal Cell, Malignant

Summary: the aim of this study was to identify psycho-social factors associated with diagnostic delay in advanced basal cell carcinomas. thus, the objective is to develop recommendations to better identify cbca populations at risk, improve earlier their diagnosis and thus their care with an adequate and targeted information.

skin cancers incidence is constantly increasing as a result of ageing of the population, and is then a critical issue of concern. among skin cancers, basal cell carcinoma is the most common. its treatment is mainly based on surgery that has to be done early. indeed, cbc can lead to progressive destruction of tissues and significant morbidity in advanced stages. in these advanced stages (cbca), they are no longer accessible to surgery or radiation therapy. the recently developed targeted therapies represent a significant therapeutic progress. to date, there are few data -none in france- concerning the cause of diagnostic delay . thus, the main goal of this study will be to evidence the brakes and facilitators who chair the decision-making to consult in patients with a cbca, by investigating: * the perception of the target subjects (patients); * the perception of the healthcare team; we will also conduct a critical meta-synthesis (qualitative meta-analysis) of the literature concerning the diagnostic delay and decision-making in onco-dermatology. it is a prospective non-interventional exploratory qualitative study without direct individual benefit

Eligibility criteria:
inclusion criteria: * patients over 18 years of age with a cbca supported for less than 12 months in the onco-dermatology unit of the chu de bordeaux. * are defined as locally advanced,tumors with major invasion of adjacent structures, that are not accessible for surgical resection or radiotherapy, . * patients will sign a consent after reading the fact sheet explaining the objectives of the study. exclusion criteria: * subjects with severe dementia (mini mental state less than 10) * an anonymized list of non-included according to this criterion will be carried out in order to quantify the number of advanced cbc with severe dementia and also the number of refusals.

Keywords: carcinoma, basal cell psycho-social factors
thrombocytopathy in gaucher disease patients

Conditions: Gaucher Disease; Thrombocytopathy

Summary: in gaucher disease type i bleeding is a common presenting symptom, that may manifest itself as frequent nose bleeds, easy bruising but can also cause substantial bleeding after surgical or dental procedures and may occur in association with pregnancy or delivery . the bleeding tendency is usually considered to be secondary to thrombocytopenia however 50,000 platelets are enough in healthy people to give a normal bleeding time but are associated with significant bleeding tendencies in gaucher patients. bleeding tendency might be attributed by genetic inherited or gaucher related coagulation factors abnormalities which in some cases stabilize with ert. however, in other cases the etiology is an abnormality of platelet function. this thrombocytopathy has not been delineated and apart from a few aggregation studies, no systematic analysis has been published that convincingly shows the cause of the disturbed function. while, experience shows that enzyme replacement (ert, i.e: imiglucerase, cerezyme®) reduces this bleeding tendency, in part due to the improvement in the thrombocyte count and elevation in coagulation factors, it is less clear what effect ert has on the thrombocytopathy. this has clinical significance when patients need to be prepared for surgery or delivery or in the event of a major bleed. there is no consensus as to how patients should be prepared or treated. different centres use different approaches. when the procedure is elective ert is appropriate but in other situations ddavp, fresh frozen plasma and platelet infusion are possible treatments. even activated factor vii has been used when bleeding was not controlled. as in any other coagulation abnormality, treatment should be tailored to the specific cause of the bleeding diathesis. the aim of this study is to define the etiology of platelet dysfunction in gaucher patients. hypothesis: the investigators expect to see a difference between platelets activation profile among imiglucerase treated and untreated patients with at least a partial restoration of platelets function due to treatment commencement.

objectives: delineating the cause of the thrombocytopathy in gaucher disease patients: 1. identifying thrombocytopathy among a cohort of 70 gaucher patients managed (treated and untreated) in our clinic using a panel of platelets function tests. 2. understanding the etiology for platelets dysfunction in gaucher disease. 3. evaluating the impact of imiglucerase treatment duration and gaucher disease severity on platelet function

Eligibility criteria:
inclusion criteria: * gaucher disease patients * patients who do not receive any medicine that affects platlats exclusion criteria: * treatment with enzyme replacement therapy other than imiglucerase

Keywords: gaucher disease thrombocytopathy imiglucerase
the validity and reliability of a wearable system for assessing turning characteristics.

Conditions: Ambulation Difficulty

Summary: the validity and reliability of a wearable system for assessing turning characteristics.

subjects are reclaimed to finish several turning task under different turning angle. the wearable system is patched on both subjects' legs and waist, to assess turning characteristics under different turning angle.

Eligibility criteria:
inclusion criteria: * able to walk 10 m independently without any device. exclusion criteria: * dizzy causing by eye disorders or vestibular disease. * any disease which involved in gait performance. * can't follow the order by investigator during task.
observational study of icd and pacemaker sensing in the presence of imed-4 operation

Conditions: Heart Failure

Summary: the purpose is to monitor far field sensing artifacts of crm devices in the presence of the imed-4

the implanted crm device will have shock therapy and rate sensor temporarily deactivated or placed in magnet mode during the time the imed-4 is activated. the imed-4 will be activated for a time not to exceed 15 minutes. during the time the imed-4 is active, the crm device programmer will print the voltage sensing of the implanted lead in real-time. the printout will be examined for the presence of far-field sensing artifacts.

Eligibility criteria:
inclusion criteria: * subjects with an active implantable crm device * subjects \> 18 years of age * subjects who are ambulatory not requiring assistance for ambulation * subjects who have been informed of the nature of the study and agree to its provisions and have provided written informed consent as approved by the irb exclusion criteria: * subjects who are pregnant or lactating or who have been pregnant within the past three months * subjects who have tattoos on the back in the electrode patch placement region * subjects who have had a past allergic reaction to adhesives * subjects who have poor general physical/mental health that, in the opinion of the investigator, will not allow the subject to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, shortened life expectance, etc.)